These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6764836)

  • 1. Specific adoptive immunotherapy: experimental basis and future potential.
    Greenberg PD; Cheever MA; Fefer A
    Surv Immunol Res; 1982; 1(1):85-90. PubMed ID: 6764836
    [No Abstract]   [Full Text] [Related]  

  • 2. Specific adoptive immunotherapy.
    Greenberg PD; Klarnet JP; Kern DE; Okuno K; Riddell S; Cheever MA
    Prog Clin Biol Res; 1989; 288():349-61. PubMed ID: 2785692
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells.
    Greenberg PD; Kern DE; Cheever MA
    J Exp Med; 1985 May; 161(5):1122-34. PubMed ID: 3921652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effector mechanisms by which adoptively transferred T cells promote tumor eradication.
    Greenberg PD; Kern DE; Jensen MC; Klarnet JP; Cheever MA
    Prog Clin Biol Res; 1987; 244():127-35. PubMed ID: 2958868
    [No Abstract]   [Full Text] [Related]  

  • 5. H-2 restriction of adoptive immunotherapy of advanced tumors.
    Greenberg PD; Cheever MA; Fefer A
    J Immunol; 1981 Jun; 126(6):2100-3. PubMed ID: 6453154
    [No Abstract]   [Full Text] [Related]  

  • 6. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes.
    Greenberg PD; Cheever MA; Fefer A
    J Exp Med; 1981 Sep; 154(3):952-63. PubMed ID: 6974221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of established tumor by adoptive immunotherapy with specifically immune T cells.
    Greenberg PD; Cheever MA
    Surv Immunol Res; 1985; 4(4):283-96. PubMed ID: 3879738
    [No Abstract]   [Full Text] [Related]  

  • 8. Models for syngeneic adoptive chemoimmunotherapy of murine leukemias.
    Fefer A; Einstein AB; Cheever MA; Berenson JR
    Ann N Y Acad Sci; 1976; 276():573-83. PubMed ID: 1088388
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia.
    Greenberg PD
    J Immunol; 1986 Mar; 136(5):1917-22. PubMed ID: 3485134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Which T cells cause graft rejection?
    Loveland BE; McKenzie IF
    Transplantation; 1982 Mar; 33(3):217-21. PubMed ID: 6801833
    [No Abstract]   [Full Text] [Related]  

  • 11. Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor.
    Eberlein TJ; Rosenstein M; Spiess P; Wesley R; Rosenberg SA
    Cancer Immunol Immunother; 1982; 13(1):5-13. PubMed ID: 6984355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential uses of interleukin 2 in cancer therapy.
    Cheever MA; Thompson JA; Peace DJ; Greenberg PD
    Immunobiology; 1986 Sep; 172(3-5):365-82. PubMed ID: 3492434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive chemoimmunotherapy of murine leukemia: dissemination, survival, and function of helper T lymphocyte clones.
    Bookman MA; Groves ES; Matis LA
    Prog Clin Biol Res; 1987; 244():93-103. PubMed ID: 2958876
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumor immunotherapy by local injection of interleukin 2 and non-reactive lymphocytes. Experimental and clinical results.
    Forni G; Cavallo GP; Giovarelli M; Benetton G; Jemma C; Barioglio MG; De Stefani A; Forni M; Santoni A; Modesti A
    Prog Exp Tumor Res; 1988; 32():187-212. PubMed ID: 2967522
    [No Abstract]   [Full Text] [Related]  

  • 15. Transfer of sensitised Lyt 2+ cells triggers acute rejection of pancreatic islet allografts.
    Prowse SJ; Warren HS; Agostino M; Lafferty KJ
    Aust J Exp Biol Med Sci; 1983 Apr; 61 (Pt 2)():181-5. PubMed ID: 6411053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic significance of concomitant antitumor immunity. I. LY-1-2+ T cells from mice with a progressive tumor can cause regression of an established tumor in gamma-irradiated recipients.
    North RJ
    Cancer Immunol Immunother; 1984; 18(2):69-74. PubMed ID: 6334549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells.
    Cheever MA; Thompson DB; Klarnet JP; Greenberg PD
    J Exp Med; 1986 May; 163(5):1100-12. PubMed ID: 3084700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Models of adoptive T-cell-mediated regression of established tumors.
    North RJ
    Contemp Top Immunobiol; 1984; 13():243-57. PubMed ID: 6610533
    [No Abstract]   [Full Text] [Related]  

  • 19. Tumor neutralization, immunotherapy, and chemoimmmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro.
    Cheever MA; Kempf RA; Fefer A
    J Immunol; 1977 Aug; 119(2):714-8. PubMed ID: 886192
    [No Abstract]   [Full Text] [Related]  

  • 20. Intrasplenic administration of interleukin-2 to potentiate specific chemoimmunotherapy in tumor-bearing mice.
    Nomi S; Naito K; Kahan BD; Pellis NR
    Cancer Res; 1986 Nov; 46(11):5606-10. PubMed ID: 2875791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.